OncoSil Medical (ASX:OSL) has reached a significant milestone in its European growth strategy, with the first OncoSil treatment successfully performed at Vivantes Neukölln Hospital in Berlin.
The procedure marks the second hospital in Germany to adopt the OncoSil device and represents an important step in building clinical momentum in one of Europe’s most significant healthcare markets. Vivantes Neukölln Hospital is among the largest hospitals in Berlin and forms part of the Vivantes Network for Health, Germany’s largest municipal hospital group. The hospital is widely recognised for its leadership in gastrointestinal oncology and interventional therapies, providing multidisciplinary cancer care to a large and diverse patient population.
OncoSil is designed for the treatment of patients with unresectable locally advanced pancreatic cancer (LAPC), a condition with limited therapeutic options and a poor long-term prognosis. The device enables targeted intratumoural delivery of Phosphorous-32 microparticles alongside chemotherapy, delivering a higher radiation dose directly to the tumour while minimising exposure to surrounding healthy tissue.
The successful first treatment at Vivantes Neukölln Hospital reinforces growing clinical interest in OncoSil within Germany and supports the company’s broader strategy to expand adoption across leading European centres. Germany is a strategically important market for OncoSil Medical, characterised by a high incidence of pancreatic cancer and a strong network of tertiary referral hospitals specialising in complex oncological care.
Establishing adoption at major public hospitals is a key component of OncoSil Medical’s commercial approach, aimed at increasing physician awareness, strengthening clinical confidence, and accelerating uptake ahead of the planned G-BA trial. The company views early adoption at prominent institutions as critical to embedding OncoSil™ within standard treatment pathways over time.
Commenting on the milestone, Chief Executive Officer and Managing Director Nigel Lange said the first treatment at Vivantes Neukölln Hospital was particularly meaningful as it represents the second German hospital to adopt the therapy. He noted that achieving adoption at another leading institution ahead of the initiation of the G-BA trial is an important step in building awareness and clinical momentum within the German healthcare system. Mr Lange added that the company is encouraged by increasing interest from German clinicians seeking innovative localised treatment options for patients with locally advanced pancreatic cancer.
OncoSil has already received CE Marking approval, allowing commercial use across the European Union and the United Kingdom, and is designated as a breakthrough device in both Europe and the United States. The device is approved for sale in more than 30 countries, with commercial treatments already undertaken across multiple European markets, as well as Israel and the UK.